Scott Beeser

Partner
P: 647-776-7309
Email    PDF    VCard
  • Called to the Bar of Ontario, 2003
  • LL.B., Osgoode Hall Law School, 2002
  • Ph.D., Doctor of Philosophy (Biology), University of Utah, , 1999
  • B.Sc., Bachelor of Science (Biochemistry), Concordia University, 1992
Scott Beeser Photo ©2025 Blaney McMurtry LLP
 Overview

Scott is a partner with significant first-chair trial and appeal experience in the pharmaceutical and information technology sectors, including at the Supreme Court of Canada. For more than 20 years, he has a proven track record in high-stakes litigation under the Patented Medicines (Notice of Compliance) Regulations. For his pharmaceutical clients, Scott has also developed and successfully implemented many novel patent and regulatory strategies, including acting as lead counsel on one of the first successful pharmaceutical summary trials that invalidated patent claims on a blockbuster erectile dysfunction drug.

Scott’s client-centric approach was shaped by his prior in-house counsel experience at a large Canadian generic drug manufacturer. Scott strives to always obtain the best client result in the most efficient manner for all patent, trademark and copyright matters.

Scott is also a registered Canadian patent and trademark agent and maintains a procurement practice on behalf clients in a wide variety of technical areas.

Prior to becoming a lawyer, Scott obtained an Ph.D. in biology from the University of Utah.

 Education
  • LL.B., Osgoode Hall Law School, 2002
  • Ph.D., Doctor of Philosophy (Biology), University of Utah, , 1999
  • B.Sc., Bachelor of Science (Biochemistry), Concordia University, 1992
 Practice Areas  Called to the Bar
  • Called to the Bar of Ontario, 2003
 Assistant  Experience
  • ELI LILLY CANADA INC., ELI LILLY AND COMPANY, LILLY DEL CARIBE, INC., LILLY, S.A. & ICOS CORPORATION INC. v. APOTEX INC., MYLAN PHARMACEUTICALS ULC, TEVA CANADA LIMITED, PHARMASCIENCE INC. & LABORATOIRE RIVA INC., 2024 FCA 72 -

    View decision here.

  • ASTRAZENECA CANADA INC. c. APOTEX INC., 2017 SCC 36 -

    View appeal here

  • SUNOVION PHARMACEUTICALS CANADA INC. & SUMITOMO DAINIPPON PHARMA CO., LTD. v. TARO PHARMACEUTICALS INC., 2021 FC 37, 2021 FCA 113 -

    View decision here.

    View appeal here.

  • ELI LILLY CANADA INC., ELI LILLY & COMPANY, LILLY DEL CARIBE, INC., LILLY, S.A. & ICOS CORPORATION INC. v. MYLAN PHARMACEUTICALS ULC et al. , 2020 FC 816, 2023 FCA 125 -

    View the decision here.

    View the appeal here

  • BIOGEN CANADA INC., BIOGEN INTERNATIONAL GMBH & ACORDA THERAPEUTICS, INC. v. TARO PHARMACEUTICALS INC. et al., 2020 FC 621, 2022 FCA 143 -

    View the decision here.

    View the appeal here

  • JANSSEN INC. & JANSSEN PHARMACEUTICA N.V. v. PHARMASCIENCE INC., 2022 FC 1218, 2024 FCA 10 -

    View decision here.

    View appeal here.

  • PAID SEARCH ENGINE TOOLS, LLC v. GOOGLE CANADA CORPORATION, GOOGLE LLC & ALPHABET INC., 2021 FC 1435 -

    View decision here

  • JANSSEN INC. & JANSSEN PHARMACEUTICA N.V. v. PHARMASCIENCE INC, 2022 FC 62 -

    View decision here

 Recognition

Recognition

  • Recognized by Best Lawyers in Canada in 2025 for Intellectual Property Law
  • Rated in IAM Patent 1000, 2024 and 2025
  • Rated in Chambers and Partners, 2024 and 2025 
 Memberships

Memberships

  • Law Society of Ontario, 2003
  • Canadian Patent Agent, 2005
  • Canadian Trademark Agent, 2005
DISCLAIMER

Thank you for your interest in contacting us by email.

Please be aware that contacting us via e-mail does not mean that the firm is acting for the sender of the e-mail. People do not become clients unless and until the firm agrees to act and that representation will be confirmed in a retainer agreement or retainer letter, in accordance with our usual policies. Unless you are an existing client, no information provided in an e-mail will be considered confidential. We ask that you do not send us specific questions on any matter until you receive confirmation that we are able to represent you.